Drug Profile
Research programme: macrophage-based nanoparticle delivery systems - Baxter Healthcare
Alternative Names: NP-IDV-BMMs - Baxter; PTX-NP-BMMsLatest Information Update: 08 Mar 2011
Price :
$50
*
At a glance
- Originator Baxter Healthcare Corporation
- Class Paclitaxels; Pyridines
- Mechanism of Action HIV protease inhibitors; Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Brain cancer; HIV-1 infections
Most Recent Events
- 19 Nov 2008 Pharmacodynamics data from a preclinical trial in Brain cancer presented at the 38th Annual Meeting for the Society of Neuroscience (SfN-2008)
- 07 Nov 2007 Preclinical trials in Brain cancer in USA (Parenteral)
- 07 Nov 2007 Preclinical pharmacodynamics data presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007)